Brands
Drug Discovery & Development
nPhase.AI becomes the industry’s first AI-native enterprise platform for end-to-end clinical data management
nPhase, a clinical research technology company, has launched nPhase.ai, the life sciences industry’s first enterprise platform for end-to-end clinical data management.
The company also introduces nPhase.ai SCE (Statistical Computing...
Clinical Trials Insights
ENA Respiratory begins part B dosing in INNA-051 phase 2a community study designed to protect against symptomatic viral respiratory infections
ENA Respiratory, a clinical-stage pharmaceutical company developing host defence enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations, has dosed the first...
Conferences and events
2026 PharmSci 360 launches two innovator-curated tracks, developed by leading scientific experts
AAPS has launched two innovator-curated tracks at the 2026 PharmSci 360.
These tracks address the current state of scientific research integrity and disruptive technologies in...
Technology and Automation
Brainomix and Endeavor present positive results from quantitative image analysis of phase2a idiopathic pulmonary fibrosis (IPF) trial
Brainomix, a leading medtech company specialising in AI-powered imaging tools for lung disease and stroke; and Endeavor BioMedicines, a clinical-stage biotechnology company, presented positive...
Drug Delivery and Supply Chain
Yourgene Health Insight DPYD assay achieves IVDR accreditation
Yourgene Health, an international molecular diagnostics company with a broad portfolio of integrated technologies and services, has announced the commercial launch of its In Vitro Diagnostic...
Conferences and events
LSX Investival Showcase London
16 November, London, UK
LSX Investival Showcase London brings together biotech innovators, medtech pioneers, healthcare investors and corporate strategics fromacross Europe and beyond, creating a...
Clinical Trials Insights
Just – Evotec Biologics advances US Department of War antibodies against orthopoxvirus into phase 1 clinical studies
Evotec SE has announced the initiation of a phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by...
Finance, mergers and appointments
Vertex Completes acquisition of Crinetics Pharmaceuticals and announces expansion of executive leadership team
Vertex Pharmaceuticals has successfully acquired Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development and commercialisation of novel therapeutics for endocrine diseases. Vertex also...
- Advertisement -
- Advertisement -
- Advertisement -bio europe 9-11 Oct
- Advertisement -WVC EU
